NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--(NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.

新泽西州新不伦瑞克（BUSINESS WIRE）--（纽约证券交易所：JNJ）今天宣布，它已经达成了一项最终协议，收购V-Wave Ltd.，这是一家私营公司，专注于为心力衰竭患者开发创新的治疗方案。

V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech..

V-Wave将加入强生公司，成为强生医疗技术的一部分。

The planned acquisition of V-Wave will extend Johnson & Johnson MedTech’s position as an innovation leader in addressing cardiovascular disease. It will further accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists..

计划收购V-Wave将扩大强生医疗技术公司作为解决心血管疾病创新领导者的地位。它将进一步加速向高增长和高机会市场的转变，并将深化与结构性介入心脏病专家和心力衰竭专家的关系。

Heart failure is a global health burden associated with impaired quality of life, frequent hospitalizations, increasing health-care costs, and high rates of premature death.

心力衰竭是一种全球性的健康负担，与生活质量受损，频繁住院，医疗保健费用增加以及过早死亡率高有关。

V-Wave’s cardiovascular implant technology specifically targets heart failure with reduced ejection fraction (HFrEF). In HFrEF, a patient’s heart muscle has insufficient ability to pump blood containing oxygen and nutrients to the body. V-Wave’s Ventura® Interatrial Shunt (IAS) is a novel implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and right atrium, thereby reducing cardiovascular events and heart failure hospitalizations.

V-Wave的心血管植入技术专门针对射血分数降低（HFrEF）的心力衰竭。在HFrEF中，患者的心肌没有足够的能力将含有氧气和营养物质的血液泵入体内。V-Wave的Ventura®房间分流术（IAS）是一种新型植入式装置，旨在通过在左心房和右心房之间产生分流来降低充血性心力衰竭中出现的左心房压力升高，从而减少心血管事件和心力衰竭住院。

Is placed in the heart through a minimally invasive catheter-based procedure and has the potential to fill a significant treatment gap between guideline directed medical therapies (GDMT) as a first line therapy and highly invasive cardiac replacement therapies, including left ventricular assist devices (LVADs) and heart transplantation..

通过基于导管的微创手术将其置于心脏中，并有可能填补作为一线治疗的指南指导医学疗法（GDMT）与包括左心室辅助装置（LVAD）在内的高侵入性心脏替代疗法之间的重大治疗差距。和心脏移植。。

Received FDA Breakthrough Device Designation in 2019 and CE mark in 2020 and has the potential to be the first device of its kind to market.

2019年获得FDA突破性设备称号，2020年获得CE标志，有可能成为同类设备中第一款上市。

Addresses an unmet need for approximately 800,000 patients who experience HFrEF in the U.S every year, representing a market opportunity for significant sustainable growth and meaningful impact.

解决了每年在美国经历HFrEF的大约800000名患者的未满足需求，这代表了显着可持续增长和有意义影响的市场机会。

Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease. We recognize the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs.

强生医疗科技公司执行副总裁兼全球董事长蒂姆·施密德（Tim Schmid）表示：“我们很高兴欢迎V-Wave来到强生医疗科技公司，并为改变心血管疾病的护理标准迈出了有意义的一步。我们认识到确定更多样化和有效的心力衰竭治疗方法的重要性，我们最近的业绩表明，我们专注于加速对最紧迫和最迫切的未满足需求的影响。

We know V-Wave well, with our relationship dating back to our original investment in the company in 2016, and we have a deep understanding of the technology and science, as well as the company’s commitment to patients. We look forward to working with the V-Wave team at this pivotal stage of its evolution to bring the Ventura® Interatrial Shunt technology to patients.”.

我们非常了解V-Wave，我们的关系可以追溯到2016年我们最初对公司的投资，我们对技术和科学以及公司对患者的承诺有着深刻的理解。我们期待着与V-Wave团队在其发展的关键阶段合作，将Ventura®房间分流技术带给患者。”。

“At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission,” said Dr. Neal Eigler, Chief Executive Officer of V-Wave. “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible.

V-Wave首席执行官尼尔·艾格勒（NealEigler）博士表示：“在V-Wave，我们致力于实现我们的愿景，帮助世界各地的患者，我们知道强生医疗科技（Johnson＆Johnson MedTech）也肩负着这一使命。”。“我们相信强生医疗技术公司处于有利地位，能够确保V-Wave的突破性想法和技术尽快有效地惠及有需要的患者。

I couldn’t be prouder of the V-Wave team, and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured.”.

我为V-Wave团队感到无比骄傲，也为它为实现这一里程碑所做出的承诺感到骄傲。我们期待着继续建设一个预防、治疗和治愈心血管疾病的世界。”。

Transaction Details, Path to Completion, and Financial Impact

交易详情、完成路径和财务影响

Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion. The transaction is expected to close before the end of 2024, subject to the receipt of applicable regulatory approvals and other customary closing conditions..

根据协议条款，强生公司将以6亿美元的预付款收购V-Wave，但需按惯例进行调整，额外的监管和商业里程碑付款可能高达约11亿美元。该交易预计将在2024年底前完成，但须获得适用的监管批准和其他惯常的成交条件。。

In accordance with U.S. GAAP, the transaction will be accounted for as an asset acquisition, resulting in a non-tax deductible in-process research and development charge of approximately $600 million in the period the transaction closes. Johnson & Johnson expects the transaction to dilute adjusted earnings per share (EPS) by approximately $0.24 in 2024 and approximately $0.06 in 2025.

根据美国公认会计准则，该交易将被视为资产收购，在交易结束期间产生约6亿美元的非免税过程中研发费用。强生预计，该交易将在2024年将调整后每股收益（EPS）稀释约0.24美元，2025年将稀释约0.06美元。

Johnson & Johnson will provide an update to its full-year financial outlook when it reports third quarter 2024 results on October 15, 2024..

强生公司将于2024年10月15日发布2024年第三季度业绩，届时将更新其全年财务前景。。

Following the completion of the transaction, V-Wave will be part of Johnson & Johnson MedTech, and financials will be reported within Johnson & Johnson MedTech’s Cardiovascular portfolio. Michael Bodner, Group President, Heart Recovery & Intravascular Lithotripsy, will assume responsibility for the V-Wave team upon close..

交易完成后，V-Wave将成为强生医疗科技的一部分，财务状况将在强生医疗科技的心血管投资组合中报告。心脏恢复和血管内碎石术集团总裁迈克尔·博德纳（MichaelBodner）将在结束后负责V波团队。。

About Johnson & Johnson

关于强生公司

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

在强生公司，我们相信健康就是一切。。通过我们在创新医学和医学技术方面的专业知识，我们拥有独特的优势，可以在今天的所有医疗保健解决方案中进行创新，以实现明天的突破，并深刻影响人类的健康。

About V-Wave

关于V-Wave

V-Wave is a privately held medical device company that was established in 2009 and is focused on developing innovative treatment options for people living with heart failure and cardiovascular disease. The company was built on a foundation of science, engineering, and medicine and has decades of experience in these fields.

V-Wave是一家成立于2009年的私营医疗器械公司，专注于为心力衰竭和心血管疾病患者开发创新的治疗方案。该公司建立在科学、工程和医学的基础上，在这些领域拥有数十年的经验。